Evidence map›Paper›PMID 38755216›Full record

ArticleScientific reports2024

Catastrophic costs incurred by tuberculosis affected households from Thailand's first national tuberculosis patient cost survey.

Sitaporn Youngkong, Phalin Kamolwat, Phichet Wongrot, Montarat Thavorncharoensap, Usa Chaikledkaew, Sriprapa Nateniyom, Petchawan Pungrassami, Naiyana Praditsitthikorn, Surakameth Mahasirimongkol, Jiraphun Jittikoon and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sitaporn YoungkongMahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. sitaporn.you@mahidol.edu.
Phalin KamolwatDivision of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Phichet WongrotFaculty of Nursing, Mahidol University, Nakhon Pathom, Thailand.
Montarat ThavorncharoensapMahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
Usa ChaikledkaewMahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
Sriprapa NateniyomDivision of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Petchawan PungrassamiDivision of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Naiyana PraditsitthikornDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Surakameth MahasirimongkolDepartment of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
Jiraphun JittikoonDepartment of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Nobuyuki NishikioriWorld Health Organization Global Tuberculosis Programme, Geneva, Switzerland.
Ines Garcia BaenaWorld Health Organization Global Tuberculosis Programme, Geneva, Switzerland.
Takuya YamanakaWorld Health Organization Global Tuberculosis Programme, Geneva, Switzerland.

Funding

Health system research Institute, Thailand HSRI 64-019World Health Organization 001
6 · The paper itself

Abstract

Tuberculosis (TB) causes an economic impact on the patients and their households. Although Thailand has expanded the national health benefit package for TB treatment, there was no data on out-of-pocket payments and income losses due to TB from patients and their household perspectives. This national TB patient cost survey was conducted to examine the TB-related economic burden, and assess the proportion of TB patients and their households facing catastrophic total costs because of TB disease. A cross-sectional TB patient cost survey was employed following WHO methods. Structured interviews with a paper-based questionnaire were conducted from October 2019 to July 2021. Both direct and indirect costs incurred from the patient and their household perspective were valued in 2021 and estimated throughout pre- and post-TB diagnosis episodes. We assessed the proportion of TB-affected households facing costs > 20% of household expenditure due to TB. We analyzed 1400 patients including 1382 TB (first-line treatment) and 18 drug-resistant TB patients (DR-TB). The mean total costs per TB episode for all study participants were 903 USD (95% confident interval; CI 771-1034 USD). Of these, total direct non-medical costs were the highest costs (mean, 402 USD, and 95%CI 334-470 USD) incurred per TB-affected household followed by total indirect costs (mean, 393 USD, and 95%CI 315-472 USD) and total direct medical costs (mean, 107 USD, and 95%CI 81-133 USD, respectively. The proportion of TB-affected households facing catastrophic costs was 29.5% (95%CI 25.1-34.0%) for TB (first-line), 61.1% (95%CI 29.6-88.1%) for DR-TB and 29.9% (95%CI 25.6-34.4%) overall. This first national survey highlighted the economic burden on TB-affected households. Travel, food/nutritional supplementation, and indirect costs contribute to a high proportion of catastrophic total costs. These suggest the need to enhance financial and social protection mechanisms to mitigate the financial burden of TB-affected households.

Indexed as

Cost of IllnessFamily CharacteristicsHealth ExpendituresTuberculosisAdolescentAdultAgedCross-Sectional StudiesFemaleHealth Care CostsHumansMaleMiddle AgedSurveys and QuestionnairesThailandTuberculosis, Multidrug-ResistantCatastrophic total costThailandTuberculosis

Identifiers

PMID38755216
PMCPMC11099064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.